Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - Entrada Therapeutics reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.86, and a significant decline from earnings of $1.55 per share a year ago, indicating an earnings surprise of -20.93% [1] - The company posted revenues of $1.95 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 78.02%, and a sharp decline from year-ago revenues of $94.69 million [2] - Over the last four quarters, Entrada Therapeutics has surpassed consensus EPS estimates three times, but has underperformed the market with shares losing about 66.3% since the beginning of the year [2][3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.93 on revenues of $8.54 million, and for the current fiscal year, it is -$3.18 on revenues of $44.01 million [7] - The estimate revisions trend for Entrada Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] Industry Context - Entrada Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]